Experimental drug - HealthQuill

Novo Nordisk will acquire US-based Akero Therapeutics, Inc. for $5.2 billion to pocket an experimental drug in end-stage trials to treat liver disease, the company announced.

Novo to buy Akero for $5.2 billion, to pocket trial liver disease drug

Novo Nordisk will acquire US-based Akero Therapeutics, Inc. for $5.2 billion to pocket an experimental drug in end-stage trials to treat liver disease,.

by HealthQuill
October 9, 2025
0 Comments

Amgen Inc.’s drug to treat advanced gastric cancer, in combination with chemotherapy, showed that people lived longer compared to chemotherapy alone, according to a company statement.

Drugs Health Pharma

Amgen’s trial drug for gastric cancer patients helps them live longer

HQ Team June 30, 2025: Amgen Inc.’s experimental drug to treat advanced gastric cancer, in combination with chemotherapy, showed that people lived longer.

by HealthQuill
June 30, 2025
0 Comments

Sage Therapeutics Inc.’s experimental drug failed to meet its main goal of treating mild dementia due to Alzheimer's disease and the US, Cambridge-headquartered company has halted its trials.

Drugs Health Pharma

Sage Therapeutics halts trials of experimental drug to treat dementia

Sage Therapeutics Inc.’s experimental drug failed to meet its main goal of treating mild dementia due to Alzheimer's disease and the US, Cambridge-headquartered.

by HealthQuill
October 8, 2024
0 Comments

Johnson and Johnson discontinued a study of an investigational drug to treat bladder cancer after it failed to yield desired results

Drugs Health Medical

J&J stops trials on drug to treat muscle-invasive bladder cancer

Johnson and Johnson discontinued a study of an investigational drug to treat bladder cancer after it failed to yield desired results

by HealthQuill
October 8, 2024
0 Comments

Gilead Sciences, Inc. has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical makers to make and sell its generic lenacapavir drug for the prevention of HIV.

Drugs Health Pharma

Gilead signs six global pacts to make, sell generic HIV preventive drug

Gilead Sciences, Inc. has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical makers to make and sell its generic lenacapavir drug for the prevention.